Pfizer (NYSE:PFE) announced today a successful phase 2 trial of its breast cancer drug Palbociclib, which had shares up 2.5% on the news. "We are delighted with the final data, which suggests the potential for Palbociclib to transform the standard of care," Pfizer announced. The company could file for accelerated approval in March, which would potentially mean approval this year.

In this video, Motley Fool health-care analyst David Williamson looks at the competition in this space, the potential market for Pfizer's new drug, and one secret winner that stands to benefit here.

What's the best way for investors to play the highly volatile biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

David Williamson owns shares of Novartis and Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.